Search | Clinical Trials Finder

Conditions: Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
Interventions: Arformoterol tartrate inhalation solution, Arformoterol 25 ųg BID, Formoterol 12 ųg BID, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 35 Years and older
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 60
States / cities: Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 56 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Aclidinium/formoterol 400/12μg, Formoterol; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: BI 1744, bi1744, Placebo, Foradil; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 11
States / cities: Tampa, Florida • Overland Park, Kansas • Lafayette, Louisiana + 7 more

Conditions: COPD
Interventions: Racemic formoterol, Arformoterol tartrate inhalation solution; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 35 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 6
States / cities: Long Beach, California • Fort Lauderdale, Florida • Raleigh, North Carolina + 3 more

Conditions: Asthma
Interventions: tiotropium bromide, Salmeterol, Formoterol, Fluticasone propionate, budesonide; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: BI 1744 (Olodaterol) Low Dose, BI 1744 (Olodaterol) Medium Dose, Placebo, Foradil; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 13
States / cities: Jasper, Alabama • Clearwater, Florida • DeLand, Florida + 10 more

Conditions: Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive
Interventions: Indacaterol, Formoterol (12 µg b.i.d.), Tiotropium (18 µg o.d.), Placebo to Indacaterol, Placebo to Formoterol; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 2,059 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 221
States / cities: Anniston, Alabama • Birmingham, Alabama • Homewood, Alabama + 163 more

Conditions: Asthma
Interventions: 80/2.25 μg Symbicort pMDI, 80/4.5 μg Symbicort pMDI, Foradil Aerolizer 12 μg, 40 μg budesonide HFA pMDI, placebo HFA pMDI; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 20
States / cities: Huntington, California • Long Beach, California • Mission Viejo, California + 17 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: PT005 MDI, Formoterol Fumarate 12 μg (Foradil® Aerolizer®), Formoterol Fumarate 24 μg (Foradil® Aerolizer®), Placebo MDI; Drug · Other
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 3
States / cities: Clearwater, Florida • Tampa, Florida • Spartanburg, South Carolina

Conditions: Exercise-induced Bronchospasm
Interventions: arformoterol, formoterol, placebo; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 12 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Formoterol Fumarate, Foradil Aerolizer; Drug
Lead sponsor: Dey; Industry
Eligibility: 40 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 4
States / cities: Clearwater, Florida • DeLand, Florida • Greenville, South Carolina + 1 more

Conditions: Chronic Obstructive Pulmonary Disease, COPD, Chronic Bronchitis, Emphysema
Interventions: formoterol fumarate; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 40 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: PT005 MDI, PT001 MDI, PT003 MDI, Formoterol Fumarate 12 μg (Foradil® Aerolizer®); Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 10
States / cities: Glendale, Arizona • Fullerton, California • Los Angeles, California + 7 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: PT003 MDI, PT005 MDI, Placebo MDI, Tiotropium bromide 18 μg (Spiriva Handihaler®), Formoterol Fumarate 12 μg (Foradil® Aerolizer®), PT001 MDI; Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 4
States / cities: Clearwater, Florida • Charlotte, North Carolina • Medford, Oregon + 1 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Placebo, TrIP-2D, TrIP-2SS, TrIP-2SS + Foradil; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: COPD Exacerbation
Interventions: Formoterol, Placebo; Drug · Other
Lead sponsor: University of Tennessee Graduate School of Medicine; Other
Eligibility: 40 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Acute Respiratory Distress Syndrome (ARDS)
Interventions: Budesonide, Placebo, Formoterol; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 5
States / cities: Tucson, Arizona • Stanford, California • Jacksonville, Florida + 2 more

Conditions: Asthma
Interventions: Tiotropium, Salmeterol, Formoterol; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 1,070 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 13
States / cities: Jacksonville, Florida • Marietta, Georgia • Newton, Georgia + 10 more

Conditions: COPD
Interventions: Inhaled PT005, Inhaled Placebo, Formoterol Fumarate 12 µg (Foradil Aerolizer); Drug
Lead sponsor: Pearl Therapeutics, Inc.; Industry
Eligibility: 40 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Spartanburg, South Carolina

Conditions: Type 1 Diabetes
Interventions: Formoterol, Placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Asthma
Interventions: Formoterol Fumarate in the Pressair DPI, Low Dose, Formoterol Fumarate in the Pressair DPI, High Dose, Foradil Aerolizer, Low Dose, Foradil Aerolizer, High Dose, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 29
States / cities: Phoenix, Arizona • Encinitas, California • Los Angeles, California + 26 more

Conditions: Asthma
Interventions: Formatris 24µg, Formatris 12µg, Foradil P 24µg, Foradil P 12µg; Drug
Lead sponsor: MEDA Pharma GmbH & Co. KG; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Gainesville, Florida • Iowa City, Iowa • Madison, Wisconsin

Conditions: Asthma
Interventions: Formoterol Fumarate; Drug
Lead sponsor: Dey; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 2
States / cities: Long Beach, California • Medford, Oregon

Conditions: Persistent Asthma
Interventions: Formoterol 12 mcg, Fluticasone propionate 100 mcg, Fluticasone propionate 250 mcg, Fluticasone propionate 500 mcg, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years and older
Enrollment: 827 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 27
States / cities: Avondale, Arizona • North Hollywood, California • Bradenton, Florida + 21 more

Search by objective public record fields.

Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

Study of Arformoterol Tartrate Inhalation Solution and Racemic Formoterol in Subjects With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD)

The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations

Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy

PT005 MDI Dose Ranging Versus Foradil Aerolizer Study

Bronchoprotective Effect of Arformoterol in Children With Exercise-Induced Bronchospasm (EIB)

A Study Characterizing Pharmacodynamic Profiles in Subjects With Chronic Obstructive Pulmonary Disease

Perforomist Versus Foradil Evaluated by Inspiratory Capacity and High Resolution Computed Tomography (HRCT)

PT003 MDI Cardiovascular Safety Study

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD

COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers

LIPS-B: Lung Injury Prevention Study With Budesonide and Beta

Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT)

Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control

Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia in Type 1 Diabetes.

Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma

Relative Potency of Formoterol Novolizer® 12 µg Compared to Formoterol Aerolizer® 12 µg

Study in Patients With Asthma

Study of Safety of Foradil in Patients With Persistent Asthma